HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer [clinicaltrials:NCT00003002]
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer [clinicaltrials:NCT00003002]
Bio2RDF identifier
NCT00003002
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003002
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Vaccines mad ...... V non-small cell lung cancer.
brief title [clinicaltrials_vocabulary:brief-title]
HER-2/Neu Vaccine Plus GM-CSF ...... or Non-small Cell Lung Cancer
completion date [clinicaltrials_vocabulary:completion-date]
2004-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... 60 patients will be accrued.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
adenocarcinoma of the lung
stage III breast cancer
stage III non-small cell lung cancer
stage III ovarian epithelial cancer
stage IV breast cancer
stage IV non-small cell lung cancer
stage IV ovarian epithelial cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-12-12T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003002
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Phase I Study of a HER-2/Neu ...... e HER-2/Neu Expressing Cancers
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000065564
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-01-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1996-04-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-12-01T00:00:00Z
identifier
clinicaltrials:NCT00003002
title
HER-2/Neu Vaccine Plus GM-CSF ...... or Non-small Cell Lung Cancer
@en
type
label
HER-2/Neu Vaccine Plus GM-CSF ...... r [clinicaltrials:NCT00003002]
@en